Felson shows diastolic BP shows 2x risk of OA from #EULAR SP0152
— Dr. John Cush (@RheumNow) June 16, 2018
Psoriatic arthritis novel therapeutics session massivelly oversubscribed – great to see so much interest in PsA but needed a much larger room as at least as many people stuck outside room #eular2018
— Stefan Siebert (@StefanSiebert1) June 15, 2018
Top Influencers of #EULAR2018: @eular_org @RheumNow @EMEUNET @SimonRStones @philipcrobinson @genentech More 📊 https://t.co/gDfAnFeVtW
— Symplur Hashtags (@healthhashtags) June 15, 2018
Jansenn. Compliance in patients with gout on Uric acid lowering therapy at 1 yr was 51.7%. Better compliance if initiated by rheumatologist 🙂 #Eular2018 @RheumNow ABST SAT0357 pic.twitter.com/4JDvGWfp4Z
— Ronan Kavanagh (@RonanTKavanagh) June 16, 2018
Reactive arthritis seems to be decreasing. Survey of rheums suggested that they are seeing less ReA and also that if it was recurrent is was more likely to have the full triad. Ordering of tests & RX varied btwn docs SAT0384 #EULAR2018 @RheumNow pic.twitter.com/kWuvXIdVNa
— Janet (@Janetbirdope) June 16, 2018
Caution advised when interpreting studies (van den Bosch) ‘in Belgium the BASDAI probably reflects the weather more than the disease!’ #EULAR2018
— Philip Gardiner (@PhilipGardiner) June 16, 2018
News from #EULAR2018: Researchers have found that joint replacements decreased by more than half in #rheumatoidarthritis patients between 1997 and 2010: https://t.co/edrPaDk0Ml
— CreakyJoints.org (@CreakyJoints) June 15, 2018
#GAMECHANGER Sjogens syndrome meta analysis shows most RCTs are negative. PRoblem with outcomes or pt selection or drugs don't work? #EULAR2018 @RheumNow pic.twitter.com/6LECvFPd3i
— Janet (@Janetbirdope) June 15, 2018
Nice study by Gensler et al showing that TNFi and NSAIDs may work synergistically to reduce SpA radiographic progression: Using Longitudinal targeted maximum likelihood estimation (causal inference modeling) to simulate RCTs to reduce bias #EULAR2018 pic.twitter.com/0WVSblzTUR
— Meghna Jani (@MeghnaJani) June 14, 2018
A sore toe can kill you! Danish population study excluded past cancers and found pts with goit had mor cancer. Lymphoma could cause gout prior to detection but many were lifestyle cancers from alcohol & metabolic syndrome FRI0221 #EULAR2018 @RheumNow pic.twitter.com/tyYvXlgnUN
— Janet (@Janetbirdope) June 15, 2018
Pts with SpA have more neuropathic pain esp if older more disease activity enthesitis and depression FRI0211 I under recognize this and Rx may help for pain and active disease #EULAR2018 @RheumNow pic.twitter.com/B47sCTz6XX
— Janet (@Janetbirdope) June 15, 2018
Rheumatology Manpower is in trouble! With more women in work force seeing less pts and younger Rheums working less days than older ones the 2.7% of population seen is stable bit more RA follow up visits so less new pts seen. FRI0622 #EULAR2018 @RheumNow pic.twitter.com/arI0nDwpgW
— Janet (@Janetbirdope) June 15, 2018
If we think pts are inconsistent you need to see the wide variation of MD global ratings for RA pt cases. We are all over the map #EULAR2018 @RheumNow FRI0669 pic.twitter.com/crKZSbxExk
— Janet (@Janetbirdope) June 15, 2018
I now use probenecid before febuxostat. A 30% increase in CVS death is a pretty big thing for me to shoulder. I only have 1 pt who I have continued it in. And they are 25 years old.
— Philip Robinson (@philipcrobinson) June 16, 2018
Good morning from the beautiful, historic city of Amsterdam! We are excited to start the final day of #EULAR2018. pic.twitter.com/Mn5g5q4yP9
— EULAR (@eular_org) June 16, 2018
Scenes from Amsterdam. Window of opportunity … no not in the red light district. It may mean something unrelated to ERA Rx response. We'll close the door on that discussion. #EULAR2018 @RheumNow pic.twitter.com/E3I1MwR6TB
— Janet (@Janetbirdope) June 16, 2018
At least half the test costs provided in referrals to rheumatologist are a waste of $ But how do we get the message out to Choose Wisely or should we restrict certain tests from ordering by primary care such as repeating ANA or DNA if ANA neg OP0302 #EULAR2018 @RheumNow
— Janet (@Janetbirdope) June 16, 2018
Does influenza cause RA? ERA CATCH cohort compared timing of onset of RA symptoms and timing of influenza. Graphs super impose but can't prove cause & effect. SAT0678 #EULAR2018 @RheumNow pic.twitter.com/HGFgxWO0Hb
— Janet (@Janetbirdope) June 16, 2018
Dr Philip Conaghans excellent lecture on imaging shows a connection between vascular insufficiency /atherosclerotic dz leads to subchondral ischemia and OA and possibly pain. EULAR SP0151 pic.twitter.com/IgW5ueUBDX
— Dr. John Cush (@RheumNow) June 16, 2018
Dr. Janet Pope at EULAR18: Gout Cancer Connection?
Dr. Janet Pope at EULAR18 on Improving Patient Comorbidities in AS
That is exciting! Really need some easy-to-use therapies for SLE https://t.co/inPUxiqFFd
— Dr Irwin Lim (@_connectedcare) June 15, 2018
#EULAR18 @RheumNow ABST op0241 tocilizumab may reduce the incidence of vascular complications in TAkayasu Arteritis. Failure free survival 81%, 72% and 48% at 12, 24 and at 48 months, respectively. Constitutional sx at presentation & CRP affect failure free survival
— Olga Petryna (@DrPetryna) June 15, 2018
#EULAR18 @RheumNow ABST op0236 Cohort study: risk of CVD is >3 fold higher & for CVA 8-fold higher in patients with incident AAV. HR for VTE was 3.26; significantly increased for DVT (HR 6.25), but not for PE (HR 1.33). pic.twitter.com/GwE81yzvjg
— Olga Petryna (@DrPetryna) June 15, 2018
Dr. Georg Schett presented some very cool imaging w/ Extreme CT showing that RA pts treated and responding to Tocilizumab show improvement of erosions – not true healing but filling in improved w/ disease control #EULAR18 @RheumNow ABST THU0050 pic.twitter.com/4WDwhAZflP
— Dr. John Cush (@RheumNow) June 15, 2018
Dr. Jack Cush at EULAR18 on Pathophysiology and PsA
Steroids, smoking and RF + are independent risk factors for developping opportunistic infections in RA #EULAR18 #EULAR2018 pic.twitter.com/2uECYBOaxC
— irati (@iratierreuma) June 15, 2018
Very timely as I fret I may have given myself plantar fasciitis walking around at #eular2018 @RheumNow https://t.co/Nb3BuqBi7g
— Ronan Kavanagh (@RonanTKavanagh) June 15, 2018
Dr. Jack Cush Week in Review (from EULAR)
Dr. Olga Petryna at EULAR2018: TKR and Biologic Therapy
Dr. Artie Kavanaugh at EULAR 18: Biosimilar Switching Studies
Dr. Peter Lipsky at EULAR 2018: Pegloticase “Triple” study
US physicians are more prone to continue biologics through pregnancy. Per a research poster presented at #EULAR2018 pic.twitter.com/l6VsTLe7Bs
— CreakyJoints.org (@CreakyJoints) June 15, 2018
How can life sciences organizations use #wearable technology to unlock #drugsafety information? https://t.co/xzarrrJHQJ
— Deloitte Health Care (@DeloitteHealth) June 15, 2018
Summary of cerebrovascular events in Giant Cell Arteritis
via Salvarani #Eular2018#GCA #vasculitis #stroke #CVA pic.twitter.com/GVCObFuSjL
— Dr Ai Lyn Tan (@DrAiLynTan) June 14, 2018
#Visual loss in Giant Cell Arteritis
– points to considervia Salvarani #Eular2018#GCA #vasculitis #blind #blindness #glucocorticoid #ocular pic.twitter.com/RfqjsEGJ1o
— Dr Ai Lyn Tan (@DrAiLynTan) June 14, 2018
Want to follow #rheumatologists on #twitter?
Here are over 200 rheumatologists who #tweet!
👉https://t.co/uwy0mGNDZ8If you're a rheumatologist & want to be on the list, please let me know!☺️#EULAR2018 pic.twitter.com/DpnIPLBvFC
— Dr Ai Lyn Tan (@DrAiLynTan) June 15, 2018
Osteonecrosis of the #jaw & antiresorptive treatments
👉statistics, prevalence & incidencevia Roux #EULAR2018#ONJ #mandible #fracture #bisphosphonate #bisphosphonates pic.twitter.com/QOESEY7243
— Dr Ai Lyn Tan (@DrAiLynTan) June 15, 2018
When should clinicians use US in the ES clinic? ‘I use it in the 10% with low disease activity where it might change my treatment’ – Phil Conaghan at #EULAR2018 #ultrasound
— Philip Gardiner (@PhilipGardiner) June 14, 2018
When might we use MRI in a treat to target PsA clinic? Phil Conaghan provided a good case to use MRI of hands: trials of very early PsA needed! #EULAR2018 #MRI
— Philip Gardiner (@PhilipGardiner) June 14, 2018
Are you thinking of a ‘treat to target’ approach to Psoriatic Arthritis? You’ll need the GRAPPA app (free) https://t.co/zSMomrsDO2 #EULAR2018
— Philip Gardiner (@PhilipGardiner) June 14, 2018
New differences appearing between IL17/23 blockers. Ustekinumab ineffective in axSpA studies, reason unclear #EULAR2018 #axSpA
— Philip Gardiner (@PhilipGardiner) June 15, 2018
Question from the clinic: what can I give a patient with severe axSpA and Crohn’s resistant to multiple TNFis? Sekucinumab should help axSpA but no benefit Crohn’s, Ustekinumab won’t help axSpA, will benefit Crohn’s #EULAR2018 #axSpA
— Philip Gardiner (@PhilipGardiner) June 15, 2018